Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 7/20 | 0.61 |
| ▸ | GLA | P06280 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.60 |
| ▸ | MAOA | P21397 | 1/20 | 0.57 |
| ▸ | MAOB | P27338 | 1/20 | 0.57 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.53 |
| ▸ | IAPP | P10997 | 1/20 | 0.53 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | NQO2 | P16083 | 1/20 | 0.51 |
| ▸ | MMP1 | P03956 | 2/20 | 0.50 |
| ▸ | MMP2 | P08253 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | FBP1 | P09467 | 1/20 | 0.50 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.50 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30548410 | 1.00 | NFE2L2 (0.61) | NFE2L2GLATDP1MAOAMAOB | |
| SCHEMBL455051 | 1.00 | NFE2L2 (0.61) | NFE2L2GLATDP1MAOAMAOB | |
| SCHEMBL14441060 | 0.86 | GLA (0.72) | GLATDP1PTGS1IAPPKDM4E | |
| SCHEMBL5598785 | 0.85 | NFE2L2 (0.65) | NFE2L2MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL5598783 | 0.85 | NFE2L2 (0.65) | NFE2L2MAOAMAOBPTGS1PTGS2 | |
| SCHEMBL30337035 | 0.83 | NFE2L2 (0.63) | NFE2L2GLATDP1MAOAMAOB | |
| SCHEMBL79651 | 0.83 | NFE2L2 (0.63) | NFE2L2GLATDP1MAOAMAOB | |
| SCHEMBL7654865 | 0.83 | NFE2L2 (0.63) | NFE2L2GLATDP1MAOAMAOB | |
| SCHEMBL79650 | 0.83 | NFE2L2 (0.63) | NFE2L2GLATDP1MAOAMAOB | |
| SCHEMBL27674511 | 0.83 | NFE2L2 (0.63) | NFE2L2MAOAMAOBPTGS1PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116745467-A | Composition for tin or tin alloy electroplating comprising a leveling agent | 巴斯夫欧洲公司 | 2023-09-12 | — | — | CN | disclosed |
| CN-113304129-B | Application of mono-ketene monocarbonyl curcumin analogue in preparing antioxidant drugs | 温州医科大学附属第二医院（温州医科大学附属育英儿童医院） | 2022-11-08 | — | — | CN | disclosed |
| US-8674115-B2 | CRTH2 modulators | IRONWOOD PHARMACEUTICALS, INC. (US) | 2014-03-18 | — | — | US | disclosed |
| US-8592430-B2 | Quinazolin-oxime derivatives as Hsp90 inhibitors | DAC SLR (IT) | 2013-11-26 | — | — | US | disclosed |
| EP-2516416-A1 | CRTH2 MODULATORS | Ironwood Pharmaceuticals, Inc. (US) | 2012-10-31 | — | — | EP | disclosed |
| EP-2144889-B1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2012-08-29 | — | — | EP | disclosed |
| WO-2012034095-A1 | COMPOUNDS AND COMPOSITIONS AS TRK INHIBITORS | IRM LLC (BM) | 2012-03-15 | — | — | WO | disclosed |
| WO-2011079007-A1 | CRTH2 MODULATORS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | WO | disclosed |
| US-20110150834-A1 | CRTH2 MODULATORS | WELLS FARGO BANK, NATIONAL ASSOCIATION | 2011-06-23 | — | — | US | disclosed |
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2011-05-19 | — | — | US | disclosed |
| EP-2144889-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC S.r.l. (IT) | 2010-01-20 | — | — | EP | disclosed |
| WO-2008142720-A2 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | DAC SRL (IT) | 2008-11-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118258-A1 | QUINAZOLIN-OXIME DERIVATIVES AS HSP90 INHIBITORS | HSP90AB1, HSP90AA1, HSP90B1 | NFE2L2 550/4885GLA 3518/4885TDP1 287/4885 |
| US-20110150834-A1 | CRTH2 MODULATORS | HRH2, HRH1, NR1H2 | NFE2L2 126/4885GLA 3005/4885TDP1 4811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.